Adjunctive therapy in coronary thrombolysis: prostaglandins, nitrates and calcium antagonists.
Fitzgerald
D
D
Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland.
D000818:Animals; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D015425:Myocardial Reperfusion; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology; D005996:Nitroglycerin / Q000627:therapeutic use; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D005343:Fibrinolytic Agents; D011982:Receptors, Prostaglandin; D011464:Epoprostenol; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D013930:Thromboxane-A Synthase; D005996:Nitroglycerin